BioLineRx Ltd.
BLRX
$3.61
-$0.24-6.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -914.05% | 836.64% | 77.05% | 63.66% | 102.61% |
| Total Depreciation and Amortization | -63.03% | -81.61% | 174.96% | 280.09% | 140.40% |
| Total Amortization of Deferred Charges | -100.00% | -- | 1,157.63% | -- | -- |
| Total Other Non-Cash Items | 129.98% | -128.02% | -317.56% | -129.77% | -159.58% |
| Change in Net Operating Assets | 125.96% | 95.24% | -102.79% | -394.01% | -659.92% |
| Cash from Operations | 98.44% | 81.64% | -272.51% | 0.77% | -17.01% |
| Capital Expenditure | -- | -- | 137.50% | 100.00% | 59.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.89% | -148.91% | 154.72% | 148.29% | -177.17% |
| Cash from Investing | 57.15% | -149.00% | 154.70% | 148.35% | -177.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -38.06% | -39.49% | -1,302.43% | -10.19% | -578.36% |
| Issuance of Common Stock | -48.66% | -- | -12.77% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.29% | 1,157.05% | -109.45% | -134.81% | 17,920.15% |
| Foreign Exchange rate Adjustments | 258.82% | -260.78% | -15.63% | 212.50% | -10.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.84% | -180.69% | 146.08% | 66.89% | 250.00% |